• Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event
• Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027
• AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027
• Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.